Indeed, BAP1 deletions and loss of function mutations are common in many cancers (Murali et al. 2013; Carbone et al. 2020; Han et al. 2021; Yan et al. 2022), and in these tumors, xc− activity would be likely to provide extracellular cystine and tumor protection. This evidence concerns the gene BAP1 and neoplasm.